Focus on α4β2* and α6β2*nAChRs for Parkinson's disease Therapeutics

Molecular and Cellular Pharmacology

Volumn 3, Issue 1, 2011, Pages 1-6

  Pérez, Xiomara A ^a   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Dopamine; Dyskinesias; Neuroprotection; Nicotinic receptors; Parkinson's disease nigrostriatal damage

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; BENSERAZIDE; LEVODOPA; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6BETA2; UNCLASSIFIED DRUG; VARENICLINE;

ARTICLE; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DYSKINESIA; EXPERIMENTAL RAT; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN TARGETING; REGULATORY MECHANISM; STRIATONIGRAL DEGENERATION;

ANIMALIA; PARKINSONIA; RATTUS;

EID: 79952204018     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.11.01     Document Type: Article

References (61)

1. Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 2010;24:177-92.
2. Lang AE. When and how should treatment be started in Parkinson disease? Neurology 2009;72:S39-43.
3. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010;16:653-61.
4. Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology 2009;72:S65-73.
5. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 2009;78:677-85.
6. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 2009;30:41-7.
7. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010;9:1106-17.
8. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010;5:229-38.
9. Exley R, Cragg SJ. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br J Pharmacol 2008; 153 Suppl 1:S283-97.
10. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001; 4:1224-9.
11. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002;53:590-605.
12. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010;74:878-84.
13. Elbaz A, Moisan F. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 2008;21:454-60.
14. Morozova N, O'Reilly EJ, Ascherio A. Variations in gender ratios support the connection between smoking and Parkinson's disease. Mov Disord 2008;23:1414-9.
15. Ritz B, Rhodes SL. After half a century of research on smoking and PD, where do we go now? Neurology 2010;74:870-1.
16. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007;68:764-8.
17. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007;64:990-7.
18. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-51.
19. Quik M, O'Neill M, Perez XA. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 2007;28:229-35.
20. Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 2008;13:492-504.
21. O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Target CNS Neurol Disord 2002;1:399-411.
22. Bencherif M. Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance. Acta Pharmacol Sin 2009;30:702-14.
23. Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003;984:224-32.
24. Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327:239-47.
25. Bordia T, Campos C, McIntosh JM, Quik M. Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 2010;333:929-38.
26. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem Pharmacol 2007;74:1224-34.
27. Champtiaux N, Gotti C, Cordero-Erausquin M, et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 2003;23:7820-9.
28. Quik M, Polonskaya Y, Kulak JM, McIntosh JM. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. J Neurosci 2001;21:5494-500.
29. Quik M, Sum JD, Whiteaker P, et al. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 2003;63:1169-79.
30. Zoli M, Lena C, Picciotto MR, Changeux JP. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci 1998;18:4461-72.
31. Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007;74:1235-46.
32. *-nicotinic acetylcholine receptors. J Mol Neurosci 2010;40:91-5.
33. Salminen O, Murphy KL, McIntosh JM, et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004;65:1526-35.
34. Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008;33:2158-66.
35. Meyer EL, Yoshikami D, McIntosh JM. The neuronal nicotinic acetylcholine receptors alpha 4* and alpha 6* differentially modulate dopamine release in mouse striatal slices. J Neurochem 2008;105:1761-9.
36. * nAChR expression and function. Mol Pharmacol 2008;74:844-53.
37. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 2004;7:583-4.
38. Zhang H, Sulzer D. Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci 2004;7:581-2.
39. Zhang L, Doyon WM, Clark JJ, Phillips PE, Dani JA. Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol Pharmacol 2009;76:396-404.
40. * nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol Pharmacol 2010;78:971-80.
41. Heien ML, Wightman RM. Phasic dopamine signaling during behavior, reward, and disease states. CNS Neurol Disord Drug Targets 2006;5:99-108.
42. Sandberg SG, Phillips PEM. Phasic Dopaminergic Signaling: Implications for Parkinson's Disease. In. Cortico-Subcortical Dynamics in Parkinson's Disease. Humana Press. 2009;Ch. 3.
43. Garris PA, Walker QD, Wightman RM. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res 1997;753:225-34.
44. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009;16:982-9.
45. Fahn S. How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? Ann Neurol 2009;64:S56-S64.
46. Pezzoli G, Zini M. Levodopa in Parkinson's disease: from the past to the future. Expert Opin Pharmacother 2010;11:627-35.
47. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.
48. Fox SH, Chuang R, Brotchie JM. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res 2008;172:479-94.
49. Jenner P. Functional models of Parkinson's disease: A valuable tool in the development of novel therapies. Ann Neurol 2009;64:S16-S29.
50. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665-77.
51. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010;58:981-6.
52. Lebel M, Chagniel L, Bureau G, Cyr M. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 2010;38:59-67.
53. Cao X, Yasuda T, Uthayathas S, et al. Striatal Overexpression of {Delta}FosB Reproduces Chronic Levodopa-Induced Involuntary Movements. J Neurosci 2010;30:7335-43.
54. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Involvement of the serotonin system in l-dopa-induced dyskinesias. Parkinsonism Relat Disord 2008;14 Suppl 2:S154-8.
55. Huang LZ, Bordia T, Quik M. Nicotine treatment reduces L-dopa-induced dyskinetic-like movements in parkinsonian mice. Society for Neuroscience Abstracts 2009.
56. Bordia T, Campos C, McIntosh JM, Quik M. Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 2010;333:929-38.
57. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Annals of Neurology 2007;62:588-96.
58. Huang LZ, Campos C, Ly J, Carroll FI, Quik M. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 2010; in press.
59. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-5.
60. Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of alpha(4)beta(2) nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316-25.
61. * nAChRs in mouse, monkey and Parkinson's disease striatum. Mol Pharmacol 2007;72:52-61.